Overview
| Generic Names: | Sibutramina [Spanish]; Sibutraminum [Latin]; methylnaltrexone |
|---|---|
| Trade Names: | Medaria; Meridia; Reductil |
| PharmGKB Accession Id: | PA451344 |
Description
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines. Sibutramine is classified as a Schedule IV controlled substance in the United States. Wikipedia (source: Drug Bank)
Indication
For the treatment of obesity. (source: Drug Bank)
ATC Therapeutic Category
- A08AA:Centrally acting antiobesity products
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Sibutramine produces its therapeutic effects by norepinephrine (NE), serotonin reuptake (5-hydroxytryptamine, 5-HT) and dopamine reuptake inhibition. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. (source: Drug Bank)
Pharmacology
Sibutramine is an orally administered agent for the treatment of obesity. Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin and norepinephrine reuptake <i>in vivo</i>, but not <i>in vitro</i>. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both <i>in vitro</i> and <i>in vivo</i>. In human brain tissue, M1 and M2 also inhibit dopamine reuptake <i>in vitro</i>, but with ~3-fold lower potency than for the reuptake inhibition of serotonin or norepinephrine. Sibutramine, M1 and M2 exhibit no evidence of anticholinergic or antihistaminergic actions. In addition, receptor binding profiles show that sibutramine, M1 and M2 have low affinity for serotonin (5-HT<sub>1</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>), norepinephrine (b, b1, b3, a1 and a2), dopamine (D1 and D2), benzodiazepine, and glutamate (NMDA) receptors. These compounds also lack monoamine oxidase inhibitory activity <i>in vitro</i> and <i>in vivo</i>. (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic (source: Drug Bank)
Protein Binding
97% (to human plasma proteins) (source: Drug Bank)
Absorption
Rapid absorption following oral administration. Absolute bioavailability is not known, but at least 77% of a single oral dose of sibutramine is absorbed. (source: Drug Bank)
Toxicity
Side effects include dry mouth, anorexia, insomnia, constipation and headache. (source: Drug Bank)
Isomeric SMILES Code:
CC(C)C[C@H](C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C (source: Drug Bank)
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
|
ADRA2A |
|
Publications |
|
|
CYP2B6 |
|
Publications |
|
|
CYP2C19 |
|
Publications |
|
|
CYP3A |
|
Publications |
|
|
CYP3A4 |
|
Publications |
|
|
CYP3A5 |
|
Publications |
|
|
GNAS |
|
Publications |
|
|
GNB3 |
|
Publications |
|
|
KCNQ1 |
|
Publications |
|
|
PNMT |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| SLC6A2 |
|
(source: Drug Bank) |
| SLC6A4 |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
|
Obesity |
|
Publications |
|
|
Romano-Ward Syndrome |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
